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Introduction
The analysis of steroids for investigations in paediatric
endocrinology is a challenge for the laboratory. There are
many developmental events and pathological disorders to
be considered in providing such a service. The laboratory
must also be on the look out for anomalous results as well
as keep abreast of new analytical developments that may
improve the service. The specificity of a steroid assay for
one analyte is often not assured within a patient sample. In
practice, a result cannot be transferred with the patient if 
investigations move from one centre to another because 
of assay variabilities. These factors are attributed to 
interferences and inaccuracies probably through the 
differences in the antibodies used in the assays, also lack of
standardisation of reagents and standards. These are now
issues being addressed particularly for testosterone (1-4).
Certified reference materials in USA and Europe (native
samples with defined hormone concentrations) have been
available for many years as targets for hormone accuracy,
but have not been widely used. Immunoassays for peptide
hormones are prone to interferences from auto-antibodies
and antibodies that react with reagents (heterophilic 
antibodies-mouse antibodies in patient samples that react
with monoclonal reagent antibodies). In some (sandwich)
assays, mainly for peptide hormones, false low results are
due to high-dose hook effects. These issues will not be 
covered in the present review but have been addressed 
recently (5). Paper chromatography, thin layer chromatography
(TLC) on silica and alumina, gas chromatography (GC) and
high performance liquid chromatography (HPLC) have all 
been applied to the analysis of steroids in extracts of 
biological fluids, but only GC and HPLC are in routine 
hospital use and will thus be covered in some detail here.
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available in highly specialised centres. For steroids, those
reference methods have relied upon stable-isotope dilution
analyses with GC coupled with mass spectrometry (MS) (6-8).
The dual selectivity of the separation of a mixture 
of components and specific ion detection enables 
exceptionally high accuracy without interferences (9-13).
Some immunoassays have approached that level of 
accuracy, but only when the method includes extraction
and chromatographic purification, again limited to very 
specialised laboratories (14,15). A number of novel mass
spectrometric techniques (fast atom bombardment, for
example) looked to have the potential for more general
analytical use (16), but did not stand up to rigorous clinical
use and needed highly skilled operators. Tandem MS now
looks to truly have the potential to improve the quality of 
assays needed in clinical practice. 
Reference intervals are essential for interpretation of
test results. The derivation of these ranges is difficult and
expensive and complicated in normal children by issues of
consent and insufficient numbers for statistical analysis.
Samples from the outpatient paediatric population and 
hospitalised patients without endocrine disease (surgical
patients) are numerous and are a useful mechanism to
overcome supply of reference materials (17,18).
Background
Technology
Colorimetric assays for steroids were the first chemical
means for the quantitative analysis of steroids, replacing 
bio-assays that had little use in paediatrics because of low
hormone concentrations and the large sample volumes
needed to get a measurable effect. Porter-Silber 
chromogens are formed when the dihydroxyacetone 
side-chain of 17-hydroxycorticosteroids (cortisol) react with
phenylhydrazine. The Zimmerman reaction involves 
reaction of 17-ketosteroids (androgens) with dinitrobenzene.
These tests also were not specific enough for clinical 
paediatric use and have largely become obsolete apart from
a few countries, mostly outside Europe. In routine clinical
practice, immunoassays have provided much valuable 
information and will continue to be used. Radioimmunoassays
have been largely replaced with alternative labels. There are
many problems with assay specificity. In any automated
method in the laboratory, where parts of the equipment
perform repeated steps in the process, there can be 
problems with sample carry-over when a sample containing
high concentrations of the analyte precedes a sample with
low concentration. Mass spectrometric techniques have
much promise and there will be changes in endocrine 
laboratory services. New reference ranges will be needed
and this will be a challenge for paediatric laboratories. 
Bioassays have been introduced using cell preparations,
which enable more reproducible results than the classic 
experiments to assess biological activity of extracts when
tested, for example, in adrenalectomised rats or immature
animal. These novel assays are not yet in use routinely, but
have a place in some investigations that will be considered
later in this review.
MS is widely used in clinical chemistry and the 
applications can be appreciated with some 
understanding of the mechanics of the component parts.
The analytes can be drugs, steroids, amino acids and 
organic acids as small molecules. Newborn screening is an
area, where MS has brought major advances (19). There are
some basic features of MS and a number of terms will be
encountered when reading about the technology. 
Chromatographic separation is often coupled with MS 
detection and this is called a hyphenated method. The 
components of the sample after separation in gas or liquid
chromatography are introduced into the vacuum of the
mass spectrometer. MS is a technique in analytical 
chemistry based on measuring chemicals as ions in the 
gaseous state according to their weights (strictly speaking, 
according to mass and charge ratio [m/z]). MS analyses
charged particles. A mass spectrometer can be divided into
a sample inlet, source, analyser and detector, all controlled
by a computer (Figure 1). The mass spectrometer produces
ions in the source from molecules in a gas or handles ions
delivered in a gas or spray to the MS. In the ionisation 
process, fragment ions may also be produced. All mass
spectrometers operate at high vacuum to minimise 
ion-molecule reactions, scattering and neutralisation of ions.
After ions are formed in the source, they are accelerated into
the mass analyser. Once the ions enter the analyser, they
are usually sorted in an electrical field or on the time to pass
to the detector (time of flight analyzer). The quadrupole
mass spectrometer is probably among the commonest 
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Figure 1. Schematic layout of a mass spectrometer. In tandem mass
spectrometry (MS) the analyser would in principle comprise three 
analysers (quadrupoles), the middle unit being a collision cell. An ion
focussed in the first MS would be fragmented in the collision cell. In
the third MS daughter ions would then be focussed to the detector
Computer
NET SOURCE
VACUM
ANALYSER DETECTORinstrument designs now being used in clinical work, 
although ion traps have high sensitivity. The quadrupole
analyser consists of four rods. Rods operate in opposite 
pairs and each carries an Rf voltage. Only ions of the proper
m/z value can successfully traverse the entire filter to reach
the detector. Other ions are drawn into the rods. When 
scanning over a mass range, the DC potential is varied 
linearly with the Rf/DC ratio held constant and an entire
spectrum is obtained. 
The mass analyser separates ions, either in space or in
time, according to their mass to charge ratios. After the
ions are separated, they are detected and data transferred
to the computer for analysis. Most mass spectrometers
use a photomultiplier detector tube. Data analysis includes
plotting spectra, background subtraction facility, library 
search and chemical formula development, processing of
quantitative data. Several spectra can be taken per second.
Quadrupoles cover a wide mass range (typically up to 1,000
Daltons) that is in essence extendable when looking at 
multiply charged particles that have mass to charge ratios
within a lower range than the molecular weights. Many
compounds will have the same nominal or integral mass
and will not be distinguished by the usual low resolution
mass spectrometers. Resolution is defined according to the
mass of the molecules separated by a valley, and is a 
function of mass and the difference between the 2 
accurate masses. 
A mass spectrum shows the intensities of the range of
ions (m/z 50 to 900 is a typical range) from an analyte and
is a qualitative fingerprint of the molecule. Accurate 
quantitative analysis is possible with MS and some regard
the technique as a reference method, though this may not
always be the case. The acquisition of an MS can be 
justified by many laboratories through cost savings largely
from lower reagent costs. In order for mass spectrometry
to be effective, within the organisation of a clinical 
laboratory, a minimal analysis time and effort in sample 
preparation was a key element. 
The accuracies of steroid methods are variable and 
results sometimes not clinically sound for all of these 
components, particularly for low concentrations of certain
steroids in children (20-25). There is now a need to move to
accurate methodology fit for clinical purpose. There will be
a need for change in laboratory practices and external 
quailty assurance (EQA) must move away from the 
traditional approach of matching results with a peer group
and ignoring the differences between methods (1,26). 
Laboratories have to consider other factors such as sample
carry-over in automated methods (27). There is a need for
systematic reviews of tests in relation to diagnostic need
(28) this has been started for steroid assays (29).
Samples
Blood, saliva and urine are fluids available for steroid
analysis. It is important to consider the information that is
available from different tests. Each method requires 
reference range appropriate to the development of the child
and related diagnostic significance (30). Steroids in blood
are largely bound to proteins (albumin and specific proteins
such as sex hormone-binding globulin (SHBG)). The free 
steroid in blood is filtered at the salivary gland and kidney,
and steroid concentrations in saliva and urine correlate with
free hormone in blood. In the investigations of thyroid 
function, there are many methods that quantify free 
hormone concentrations in plasma. That has not been 
widely used in the steroid field. Assays for steroids after 
equilibrium dialysis or ultrafiltration have been described for
cortisol (31). Free testosterone can be determined by analogue
methods (32), ammonium sulphate precipitation (33), dialysis
and ultrafiltration. Five routine assays have been compared
with a GC-MS method based on ultrafiltration (34). The 
methods are not amenable to automation and were not 
considered important in an Endocrine Society review of tes-
tosterone determinations (1,35). Indices of free hormone are
used by some, based on a percentage of the total steroid that
can be bound to a concentration of the specific binding 
protein, i.e. free androgen index
FAI=(serum testosterone/SHBG concentration)X100
Two assays are needed, both of which are subject to 
error, particularly in prepubertal boys, when testosterone is
<5 nmol/L and SHBG above 120 nmol/L.
Blood samples can have large changes in steroid 
concentrations over a 24h period and timing can be critical,
so the laboratory need to be informed of time of collection
of any sample to assist interpretation of results. Plasma 
cortisol can be 200-800 nmol/L around 0800h and less than
150 nmol/L at midnight. This is often depicted as a sine
wave curve to illustrate a diurnal rhythm. In fact, there is a
strong pulsatile pattern during the night with 3 or 4 peaks of
increasing intensity starting around 0200h to 0300h with a
final peak between 0600h and 1000h (36). Antenatal 
dexamethasone administration in pregnancies at risk of 
preterm delivery is an established procedure to decrease
neonatal mortality. This can affect the hypothalamic-
pituitary-adrenal axis in the neonate and influence hormone
tests  (37). Whoever collects samples should check 
laboratory guidelines for sample size and container, 
because material in the containers and separating agents
and preservatives can affect assay performances (38). It
may not always be possible to get a sample sufficient for all
the tests wanted, so a priority should be discussed with the
laboratory to optimise use of sample. Laboratories need 
to preserve samples in the state they left the body, so 
separation of plasma from blood cells in a timely manner
and suitable storage around freezing temperatures or below
need to be observed and monitored (39-41).
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investigations, because collection is less invasive (42,43
and 44 for reviews). There are a number of techniques to
improve saliva flow (45). Like urine, saliva steroids reflect
the free hormones in the blood. The steroids concentrations
are thus normally very low (cortisol around 5 nmol/L) 
and sensitive assays are needed. 11-Hydroxysteroid 
dehydrogenase activity (HSD11B1) is active in salivary
glands, so saliva has high concentrations of cortisone and a
cortisol assay must be used that does not detect 
cortisone as well (46). The loss of diurnal rhythm of 
cortisol can be detected in screening for Cushing’s syndrome
(47-49). Saliva samples can be taken for analysis of 
17-hydroxyprogesterone (17-OHP) or androstenedione (AS)
to monitor congenital adrenal hyperplasia (CAH) treatment
(50,51). Because of the variations in steroid production and
low concentrations of steroids in blood and saliva, urine has
been a useful biological fluid for analysis. 
Free cortisol excretion rate in urine can be determined.
This is an important index of cortisol excess, but should 
never be used to demonstrate adrenal suppression. 
Immunoassays for cortisol in urine are not specific, being
subject to cross reaction from cortisone (52) and steroid
metabolites  (53,54). Steroids are inactivated in the liver
through a number of reductive enzyme catalysed reactions
and metabolites are conjugated with glucuronic and 
sulphuric acid to aid urinary excretion. In the neonate and
for the first six months of life, there are a number of active
enzymes (hydoxylases at carbons 1,6,15,18), which adds to
the number of steroids requiring identification in normal and
pathological states. From a 24h collection, the combined ex-
cretion rates of corticosteroid metabolites come close to
production rates. In young children, a 24h collection is 
difficult to obtain reliably, for much diagnostic work analysis
of steroids in a spot sample gives useful information. Some
laboratories are able to accept disposable diapers (free of
any faecal soiling) for certain analyses (55). Urine can be 
obtained by squeezing, pressing (hydraulic or wine press) or
centrifugation (fruit juice extractor). 
In paediatrics, there are wide changes in reference 
ranges for age, gender and stage of development that 
influence the mix of steroids present in the sample. There
are problems with samples from preterm babies and 
neonates (interferences from adrenal fetal zone steroids),
adrenarche (increase in adrenal androgen secretion) and 
puberty (changes in concentrations of binding proteins, as
well as pituitary and gonadal hormones). Furthermore,
when providing assays for the range of clinical conditions,
then results are encountered that fall outside the range of
assay calibration. Samples then need to be diluted. Ideally,
the matrix needs to be preserved, so use of the assay zero
standard is the best way to achieve this without altering the
dynamics of the assay. Many publications attest to the 
difficulties created clinically from misinterpretation of 
steroid results (see # 56 for 2 examples around 
testosterone assays).
Immunoassays of Steroids
In the 1960’s, immunoassay revolutionised the clinical
laboratory services for hormones (57). The low concentrations
in children of certain steroids often meant larger samples
were needed to achieve sensitivity in the assays. An 
extraction and concentration step was needed in some 
cases (58). In order to reduce total sample size for paediatric
samples, especially when several tests were needed, some
laboratories developed chromatographic separation of a
single sample extract before immunoassays of the 
separate components-an extremely demanding and 
time-consuming approach (14,15,59-64). Some automation
of the procedure is possible (65). Specificity of steroid 
assays is also improved by chromatography before 
immunoassay (for example paper chromatography (66) or
column chromatography with celite (67-69) Kieselguhr (70)
or using Sephadex LH-20 (71) or Lipidex, a lipophilic 
derivative of Sephadex (72,73). Since steroids are largely
bound to proteins, it is usual to measure the concentration
of the total hormone in plasma after displacement of the
steroid by extreme pH, heating or addition of a synthetic
steroid. 
Immunoassays have evolved over the years (74). 
Initially, assays were set up in-house using reagents that
were generated by the laboratory, or obtained from other 
laboratories or purchased from commercial sources. The
key components were a standard to generate a graph of
signals from the range of hormone concentrations 
(calibration curve), an antibody and a label. Antibodies were
initially created by injection of mice, rabbits or sheep with a
hapten. For steroids, it is necessary to couple the steroid to
a protein, such as bovine serum albumin of limpet 
haemocyanin, to create a significant hapten. Specificity was
improved by affecting the union of steroid to protein at a 
position in the steroid remote from the functional groups.
After several injections of the hapten, high antibody titres
were generated and serum from the animals could be 
diluted to give large volumes of the assay-ready antibody
preparation. As specificity of the antibody recognition of a
steroid improved, then confidence was gained to use 
biological samples directly in the assay tube. Prior to that 
time, steroids were extracted into an organic solvent that
was dried and reconstituted in assay buffer for the analysis.
The extraction step was certainly important to separate for
neonatal samples, in which the presence of fetal adrenal 
zone steroid sulphates needed to be stripped from free 
steroids in the samples, so as to reduce to interference in
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illustration of the lowering of 17-OHP results in an assay 
based on solvent extracts compared with plasma itself). In
some cases, steroids in the organic extract were purified by
chromatography (76) and the eluates from an HPLC could be
collected in timed fractions (77).
At the outset, carbon-14 and tritium labelled steroids
were commonly used and liquid scintillation counting was
required for detection of beta-radiation. The label was 
usually present in the assay tube at a concentration to react
with around 50% of the binding sites on the antibodies. 
Addition of steroid in the sample thus reduced the amount
of bound label (competitive immunoassay). After the 
reaction of analyte and label with the antibody, the free and
antibody fractions had to be distinguished. The free fraction
could be absorbed from the sample with charcoal that 
could then be precipitated with the aid of centrifugation.
Waste disposal was a big problem, so gamma ray emitting
isotopes (iodine 125, for example) were attractive, although
they had short half lives, so reagent had to be renewed on
a regular basis. To introduce iodine, labelling of a steroid
usually requires the use of a derivative of the steroid that
will react with iodine. Tyrosine and histamine conjugates of
steroids have been common substituents for this purpose,
but this then makes the label structurally different from the
natural steroid in a biological sample, so the compounds 
react differently with the antisera (78). Multi-well gamma
counters helped with rapid batch processing of 10 or 16
samples at a time. The antibody-bound fraction could be
precipitated after the addition of a second antibody (donkey
antisera to the mouse, rabbit or sheep protein), that 
increased the molecular size of the complex. Later 
techniques were developed to bind the antibody to the wall
of a reaction tube (coated tube) or to particles (beads or
magnetic particles); the free fraction in solution could then
be decanted at the end of the reaction. 
Commercial kits for 17-OHP typically are designed to
detect elevated concentrations in heterozygotes for 
classical disease and patients with non-classic forms-a
worthwhile test in the investigation of patients with 
androgen excess and infertility. Kits, however, to detect the
classical form of the disease would not be economically 
viable. Interferences in 17-OHP assays can be encountered
in the newborn period often from the fetal adrenal zone 
steroids (DHAS, pregenenolone) (79). In patients with CAH
due to 21 and 11-hydroxylase deficiency, the high 
concentrations of cortisol precursors can lead to falsely 
elevated results for cortisol (80,81).
Monoclonal antibodies were successfully generated for
many analytes, but for steroids they did not initially prove to
be as good as the polyclonal animal raised antibodies. Now,
monoclonal antibodies are attractive, because the supply of
a characterised antibody can be sustained (82-84). Some
changes in hapten have assisted antibody quality (85). 
A few methods are based around anti-idiotype assays
(86,87). Since mice are used for monoclonal experiments,
samples from patients exposed to mice (or treated with
mouse monoclonal antibody therapies) can introduce 
heterophilic antibody reactions (88). Unusually low results
for steroids can be found (89) and appropriate steps need to
be taken to counteract the heterophilic antibodies (90,91).
To overcome concerns over safety and stability of reagents, 
alternative labels were introduced (chemiluminescent, 
fluorescent, as examples) (92), and from that time 
automation gradually took over (reviewed by Wheeler # 93).
With the introduction of multi-channel automated 
analysers, it became possible for the laboratory to analyse
all the components for results of a panel of hormones 
(cortisol, progesterone, oestradiol, testosterone, T3, free
T4, DHAS, LH, FSH, TSH, prolactin, ACTH) in one sample
over a few hours. Multi-channel, automated methods really
needed to have the same incubation steps for each analyte
and inevitably optimisation for certain assays had to be
sacrificed. In general, steroid assays take longer times to 
reach equilibrium than peptide assays. 
Automated immunoassay systems have been evaluated
in the paediatric setting and found to be acceptable (94-96).
Problems have inevitably been encountered with 
automated methods in the laboratory. In immunoassays, 
results for testosterone in newborns have been reported to
be grossly elevated (20) due to interferences from fetal and
placental steroids. One publication reported that, when
samples were tested for testosterone after the same 
sample had just been tested for oestradiol (97), high 
concentrations of testosterone were indicated. This was
explained by carry-over of reagents in the sample probe, 
rather than sample, because direct steroid assays need to
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Figure 2. Direct assays for 17-hydroxyprogesterone (17-OHP) give
higher results than when a solvent extract of a sample is analysed. 
Interferences in the assay from fetal adrenal steroid sulphates are
removed by the extraction from reference 75, with permission
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proteins (for example, testosterone in the oestradiol assay).
Such problems are not easy to resolve, because the 
formulation of assays is not described in detail by the 
instrument manufacturers. The information on cross 
reactivity is another area where kit information may not be
entirely valid. Ideally, a displacement curve should be 
plotted for any potential interfering compound. Cross 
reactivity is then expressed from the 50% binding 
concentration of the interferent relative to the concentration
of the analyte at that point in the calibration curve (then 
usually expressed as a percentage cross-reaction). Many kit
manufacturers take an approach of adding a concentration
of the interferent that is assumed to be greater than ever
encountered in biological samples and assessing the 
concentration measured as a percentage of the amount 
added. DHAS can cross react in the testosterone assay on
the Abbott Architect (98). 
A metabolite of an interferent can be more potent in the
immunological reaction and create a falsely high result. 
Metabolites are not always available and indirect 
evidence is needed to support proof. For instance, in an 
androstenedione assay, elevated concentrations can be 
apparent in samples collected from patients taking 
spironolactone. The cross reactivity was reported to be less
than 0.01%, but androstenedione returned to the normal
range when treatment was withdrawn, suggesting 
interference, probably from the metabolites rather than the
drug itself (Honour and Dawnay, unpublished) (see Table 1).
Low concentrations of steroids are difficult to assay. Direct
immunoassays are not sufficiently accurate and specific for
oestradiol in children (23) or androgens in the investigation
of disorders of sexual development (56,99,100).
Gas Chromatography
Although many investigations have relied upon analysis
of steroids in blood samples, the analysis of urinary 
steroids by GC has proved to be a very powerful tool 
with the ability to recognise most of the steroid 
disorders in children from characteristic steroid profiles
(metabolomes) (101,102). In fact, many of the 
recently discovered disorders of the adrenal cortex can be
credited to this technique pioneered in 1970 by Cedric
Shackelton, who has ever since made seminal contributions
to this diagnostic area (see Table 2 for summary of these
achievements). Steroids need to be extracted from urine;
solid phase extraction is commonly used for this. Steroid
conjugates are hydrolysed using glucuronidase and 
sulphatase enzyme preparation. After re-extraction of 
steroids, methyloxime-trimethylsilyl ether derivatives are
formed. These make the steroids stable for high temperature
GC separation and direct fragmentation in the MS. Steroids
eluting from a GC column can be detected non-selectively
by a flame ionisation detector, the identification is by 
retention time. If the effluent is directed to a mass 
spectrometer, then hundreds of spectra can be taken from
mass to charge 50 to 1000 over a 30 minute GC run. Each
spectrum is a fingerprint of the steroid. For the detection of
gross changes in steroid production, a spot sample of urine
can provide enough information in a steroid profile from
whether individual and groups of steroids are low, normal or
raised. In CAH, there will be low levels of cortisol 
metabolites, raised concentrations of intermediates (such
as 17-OHP metabolites), and low or raised androgens, 
depending on the affected enzyme. As a result of the 
pattern of high cortisol production during the night, the 
highest urinary excretion rates of the cortisol metabolites is
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Table 1. Endocrine results in patient with polycystic ovary syndrome before and on treatment with spironolactone 
LH FSH Testosterone DHAS AS
PRE-TREATMENT
1 13.9 6.6 5.2 7.5 9.5
2 19.5 7.9 7.9 6.0 16.1
3 42.4 12.4 1.6 2.7 11.8
4 11.6 5.0 3.3 8.9 7.9
5 4.5 5.2 1.5 5.7 6.5
ON-TREATMENT
1 16.3 7.8 6.3 7.2 37.5
2 19.7 8.3 8.3 23.0
3 33.2 4.3 4.9 8.5 98.1
4 6.7 5.7 3.7 3.6 47.6
5 4.4 8.3 1.4 2.8 30.5
LH: Luteinizing hormone, FSH: Follicle stimulating hormone, DHAS: Dehydroepiandrosterone sulfate, AS: Androstenedionbetween 1000h and 1800h (103), so it is not wise to collect
spot samples in the early morning or afternoon for 
assessment of cortisol production on this basis. Ratios of
metabolites are diagnostic of 5-alpha reductase deficiency
and defects of HSD11B1 (high cortisone) and HSD11B2
(high cortisol). 
In order for steroids in plasma to be detected in GC 
methods, it was necessary to make derivatives that were
suitable for sensitive electron capture detection. This was a
difficult detector to keep for routine use and will not 
be considered here. GC-MS has been found also to 
be a very reliable quantitative method for steroids in 
plasma such as DHAS, 17-OHP, AS, testosterone, 
17-hydroxpregnenolone, 11-deoxycortisol and DHAS (7-13).
It is superior to other methods, because of the improved
specificity of assays through separation of steroids in the
sample extract, which is needed particularly for tests on
newborn infants. A deuterium labelled internal standard 
steroid of high purity is used for what is effectively an 
isotope dilution analysis. The internal standard is added at
the start of the assay, so acts as a recovery marker for the
extraction and chromatography. Heptafluorobutyrate 
derivatives are most used, because of their ease of 
preparation and minimal fragmentation in the mass 
spectrometer. After GC separation, the steroids are 
fragmented usually by electron impact, and ions for the
analyte and the internal standard are monitored by the MS.
Specificity in the assay can be demonstrated from the 
relative responses for a quantifier and a qualifier ion for
each compound. Calibration curves are linear for low 
concentrations through normal levels to grossly pathological
levels in patients with CAH, where levels up to 1000 nmol/L
can be seen. There is 97-103% recovery of steroid added to 
samples across a wide range of concentrations. 
Comparison of results with a number of clinical samples 
assayed by a direct and an extracted RIA showed close 
agreement with extracted RIA’s. Most laboratories will not
measure 17-OHP in the first 3 days after birth because of
false high results due to interference from fetal adrenal 
zone steroids like 17-hydroxypregnenolone and its sulphate
(79). The GC-MS method is not subject to these 
interferences and reliable results can be obtained in 
affected children within 12h of birth. Internal QC shows low
CV’s compared with immunoassay methods. In external
EQA, the GC-MS method performances have also been 
impressive with CV’s less than 3%. Only 500 microlitres of
sample is normally used but when necessary 50 microlitre
sample can be used without compromising a result. Normal
ranges at different ages and genders are available, as well
as reference ranges for Synacthen tests. These values are
different to results from immunoassays. This assay has 
been compared with MS/MS, but the GC/MS has a very
7
Honour JW
Steroid Assays in Paediatric Endocrinology
Table 2. Applications of urinary steroid profile analysis by GC-MS
1. Inborn errors of steroid metabolism. These include
(A) Congenital adrenal hyperplasia (CAH) due to deficiency of: 
• Pregenenolone synthesis resulting from StAR protein defect in cholesterol uptake or, more rarely, cholesterol side chain cleavage enzyme
(CYP11A1)  defect (lipoid adrenal hyperplasia)
•3 β-hydroxysteroid dehydrogenase (HSD3B2)
•1 7 α-hydroxylase (CYP 17)
•1 1 β-hydroxylase (CYP 11B1)
• 21-hydroxylase (CYP 21A2)
• Cytochrome P450 oxidoreductase (POR, associated with Antley-Bixler syndrome) 
• 11-hydroxysteroid dehydrogenase I (HSD 11B1, cortisone reductase, usually apparent, due to an intronic mutation combined with a hexose 6 phos-
phate dehydrogenase mutation)
• 7-Dehydrocholesterol reductase (DHCR7, associated with Smith Lemli Opitz syndrome, SLOS)
• glucocorticoid receptor action
(B) Deficiency of
•5 α-reductase (SRD5A2)
• steroid sulphatase (STS)
• aldosterone synthase (CYP 11B2)
• aromatase (CYP19)
• 11-hydroxysteroid dehydrogenase II (HSD 11B2, apparent mineralocorticoid excess, AME)
2. Steroid-secreting tumours
3. Steroid resistance
4. Adrenocortical hyper- and hypofunction
5. Changed steroid metabolism due to drug treatment (eg metyrapone, ketoconazole) or to clinical condition (eg  Cushing’s syndrome, anorexia nervosa)high standard to beat. Any child with ambiguous genitalia at
birth needs a 17-OHP result as soon as possible; this 
method meets the criteria, with results less than 3 nmol/L
in normal infants from the first day of life, and clearly 
elevated above 100 nmol/L in a child with 21-hydroxylase 
deficiency. 
Just as profiles of steroids by GC and GC-MS reveal 
information to recognize abnormal patterns with adrenal 
disorders then GC-MS-MS provides additional information.
GC-MS–MS in product ion scan mode enables the 
recognition of most steroids in the sample through the
combination of retention time and fingerprint of the mass
spectrum. The nature of unknowns can also be approximated
(104). GC coupled with tandem mass spectrometry 
(GC-MS-MS) (MS1 selecting ions, MS2 scanning 
fragments) can give even greater power to identification of
steroids. Recently, more than 120 steroids were characterised
in the urine of patients with CAH due to 21-hydroxlase 
deficiency (104). The sum of glucocorticoid metabolites in
urine (TCM) collected for 24h approximates the daily 
production rate of (105,106) and is an excellent test for 
adrenal suppression (107). The improved sensitivity of 
LC-MS-MS methods shown for androgens and oestrogens
(to<10 pmol.L) will now allow earlier and more accurate 
assessments of pubertal development (108). Even before
signs of puberty, girls had higher androgen and oestrogen
levels than boys.
Liquid Chromatography
Steroids can be separated by reverse phase HPLC and 
detected with UV spectroscopy for some diagnostic work 
(76,109-115). In reverse phase chromatography, a typical 
elution order will be aldosterone, cortisol, DHAS, corticosterone,
11-deoxycortisol, AS, testosterone, DHA, 17-OHP and 
progesterone. This approach is only successful, when 
sample concentrations of the steroids are in excess of 200
nmol/L-i.e. for cortisol and DHAS under normal circumstances
and raised concentrations of intermediates in patients with 
disorders of cortisol synthesis. Sample processing is minimal
and results can be available within hours of sample receipt in
the laboratory. 
In LC-MS, the effluent from HPLC is directed through a
capillary to the source of the mass spectrometer. The 
temperature of the capillary is adjusted to a level, where the
solvent is partially vaporized (Thermospray). This generates
a supersonic jet of vapour that contains a mist of electrically
charged particles. The ion chamber is evacuated and 
solvent continues to leave the droplets concentrating 
charge at the surface. Eventually, ions are expelled and 
leave the thermospray source through a small orifice in the
sampling cone. Ammonium acetate is often incorporated 
into LC solvent systems to accelerate the ionisation 
process here. 
Cortisol, being in blood at 200 to 800 nmol/L as opposed
to 17-OHP around 5 nmol/L, can be measured by LC/MS
without the lengthy sample work-up and derivative formation
needed in a GC-MS method. This methodology has also 
been used to establish the production rate of cortisol. 
Previously, radioactive methods had been used giving 
results around 18 milligrams per day (116). Clinicians were
comfortable with that, because replacement treatment is
usually at around that level, but no treatment regimen yet
replaces the normal pattern of cortisol concentrations in
blood over the 24 hours. When stable isotope dilution 
methods were used, cortisol production rate is 6 to 9 
milligrams per metre squared with most secretion between
0200 and 0800h (117) as expected from blood concentrations
when samples are taken at 10 minute intervals. Stable isotope
dilution LC-MS has been used for 17-OHP in plasma (118).
Fast atom bombardment in the mass spectrometer was
a technique of great promise some years ago, but did not
get widely adopted and is rarely used today. A steroid 
extract could be dissolved in glycerol and put on the 
whiskers of a probe where the sample was desorbed and
ionised by being bombarded with fast Xenon or caesium
ions. Steroid conjugates did not need to be hydrolysed and
mass spectral patterns were obtained of individual steroid
(119). Abnormal results were seen for glucuronide 
conjugated steroids in CAH (16). When pregnancy urine
was analysed by FAB MS, the profile from a normal 
pregnancy could be distinguished from a pregnancy with
placental sulphatase deficiency by the presence in the 
latter of DHAS metabolites. The instrumentation needed 
regular cleaning and maintenance and was not suitable for
processing large numbers of samples.
Liquid chromatography coupled with tandem mass
spectrometry (LC-MS-MS) now has the potential for 
steroid analysis in paediatric samples. Tandem MS is a
combination of mass spectrometers to improve analytical
performance. More detail about the technology can be 
found in recent reviews (120). MS coupled with MS 
(tandem MS) enables sequential filtration, fragmentation
and focussing of ions. The collision cell is similar to the 
quadrupole analysers at MS1 and MS2, so some systems
use the term triple quad for a tandem mass spectrometer.
Each MS can select specific ions or scan a mass range 
looking at a spectrum of ions. For quantitative MS, multiple
reaction monitoring (MRM) is used. For a description of 
other modes, see Chace 2009 # 19 for a review. In an
MRM, the first MS (MS1) affords sample purification by 
selecting an ion of mass to charge for the required analyte.
Between the two MS sectors, a collision cell can produce a
region for fragmentation of the ion that penetrated the first
MS. The second MS (MS2) is set to transmit a fragment
ion; characteristic of the analyte can be operated as a 
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MS, fragmented, then sorted to monitor intensity of ions in
second MS. The combination after LC separation thus adds
sensitivity and specificity. 
In the source, neutral molecules are ionised, then 
accelerated into the mass analyser. In electrospray, 
ionisation takes place at atmospheric pressure. A large 
electrical potential is applied to the metal inlet needle 
bringing the sample out of the HPLC. As the HPLC effluent
liquid leaves the nozzle, the electric field induces a net 
charge on the small droplets. As the solvent evaporates,
the droplet shrinks and the charge density at the surface of
the droplet increases. After further evaporation, the droplet
explodes and release charged analyte ions. Most 
androgens and intermediate steroids are measured as 
positively charged ions; some corticosteroids are measured
as negative ions, aldosterone, for example (121). In a few
cases, derivatives are formed to assist ionization and assay
sensitivity, notably for oestrogens (122,123) and steroid
conjugates (124).
Stable isotopes are very useful in a number of ways in
clinical investigations and make for ideal internal standards
in quantitative MS analysis. A range of stable-isotope 
labelled steroids are commercially available (Table 3). In the
LC analysis, the isotopic steroids move slightly faster than
the unlabelled analyte; when 5 or more deuterium atoms
are included, the two steroids will almost separate, so in 
effect, the carrier effects of the 2 that protect against 
system losses can be negated. Due to the natural 
distributions of isotopes of the elements, all compounds in
a mass spectrometer give a cluster of ions, notably at M+1
and M+2 Daltons. If the stable isotope steroids had 2 
deuterium atoms, then it effectively is indistinguishable
from natural isotopes of the analyte. Ideally, a labelled 
steroid for use, as an internal standard in MS, should have a
mass increment of 3-6 Daltons. Alternatives are isomers
and analogues of the analyte that separate from the analyte.
High sensitivity methods can be established, because only 2
or 4 ions need to be monitored for an effective analysis with
the MS used in ion monitoring mode. The intensities of at
least 2 ions from the analyte and 2 ions from the internal
standard are recorded with time. A typical set of ions 
monitored is shown in Table 4. Sensitivity is increased 
about 500-fold compared with scanning mass range and
processing ion signals relevant to the analysis. Response
ratios for the ions are as seen in the spectrum. Usually, the
most intense ion in the spectrum is used for the 
quantitative analysis and as described in the GC-MS 
section, the other ion act as qualifier ion to demonstrate
specificity (125,126).
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Table 3. Examples of stable isotope labelled steroids
Carbon 13 Deuterium substitutions
Androstenedione 2,3,4-13C3 2,2,4,6,16,17-d7
Cortisol 9,11,11,12-d4
DHA 16,16-d2
Testosterone 3,4-13C2 16,16,17-d3
17-hydroxyprogesterone 1,2-d2
11-deoxycortisol 21,21-d2
Corticosterone 2,2,4,6,6,17,21,21-d8
Aldosterone 2,2,4,6,6,17,21,21-d8
Table 4. Typical transitions monitored in LC-MS-MS for steroids
Q1 Q2
Quant (Qual) Quant (Qual) Possible interfering steroids
Androstenedione (287) 287.2 (287.2) 97.1 (189.2)
Cortisol (363) 363.2 (363.2) 97.1 (121.1) Prednisolone (M + 2)
DHA (289) 271.2 (271.2) 213.2 (197.2)
Testosterone (289) 289.2 (289.2) 97.1 (109.1)
17-hydroxyprogesterone 331.2 (331.2) 97.1 (109.1) Hydroxyprogesterones
11-deoxycortisol (347) 347.2 (347.2) 109.1 (97.1) Dihydroxyprogesterones
Corticosterone (347) 347.2 (347.2) 121.1 (97.1) Dihydroxyprogesterones
Aldosterone 359.2 (359.2) 189.2 (331.2)
Stable isotope labelled internal standards will be monitored by separate multiple reaction monitoring (MRM) quantifier and qualifier ionsSteroids can be determined singly in samples or as a
profile. This technique will only be described in detail 
sufficient for clinicians to appreciate what the methods can
offer to paediatric endocrine investigations and review the
applications to date. Minimal sample preparation is an 
important advantage, saving time and cost. Protein 
separation being the simplest first step. The improved 
specificity of the results leads to more accurate results and
new reference ranges will be needed to interpret LC-MS-MS
results. Most of the assays are currently at the in-house 
stage, like when immunoassays were first introduced and
results need to be considered carefully. Any abnormal 
result should be discussed with the laboratory staff, so that
problems can be addressed. Interferences can still be 
encountered and these need to be catalogued, so that the
method can be modified to overcome the problem. The
equipment manufacturers are exploring options to provide
reagent kits for analytes and profiles, so introducing an 
important level of assay standardisation so desperately 
needed clinically.
Steroids and vitamin D are being analysed by tandem
MS in an increasing number of centres. Assays of steroids
in blood, urine and saliva have been reported. As yet there
has not been published much by way of QC performance to
see if MS/MS is superior to GC-MS where very good 
precision have been shown by some users as well as poor
reproducibility in other tests. Although in principle 
reference standard methodology is being used (127), the 
results do not yet meet the requirement one might 
expected. Reasons for this include matrix affects, 
procedural differences, calibration differences. The 
laboratory has an important role to play in the method 
validation, but there is an obligation for clinicians to alert the
laboratory if problems are seen with results out of keeping
with the diagnosis.
Despite the apparent simplicity of LC-MS-MS methods,
the technique suffers from suppression and enhancement
of ionization from compounds co-eluting from the LC into
the source of the MS – this is called matrix effect. This can
seriously affect the accuracy of the method and requires 
extensive validation and continuous checking of data to 
detect interferences. The use of a stable isotope internal
standard in most cases, but not all (128-132), will 
compensate for this, because the chemical similarity with
the analyte means both steroids are affected equally. 
A number of validation experiments are used, such as 
recovery of standard addition, post-column infusion of 
standard, and sample dilution (133-136). Since the method
looks at mass to charge of a compound and its fragments
in the collision cell, then any isomeric steroid will have to be
known not to interfere. The isomers will often be separated
in the LC. Compounds with the same molecular weight as
the analyte are isobaric and have potential for being 
detected like the analyte (137,138) or internal standard
(139). For testosterone, as an example, this required 
extensive testing (127). Many compounds and especially
phospholipids  (140-142), are known to interfere in these
methods; drugs can also suppress and enhance the signal
(143, 144). These issues have been reviewed (145,146) and
laboratories have the responsibility to consider carefully the
matters raised, so will not be debated further in this more
clinically orientated review. 
In the LC-MS-MS, one can really only look for 
compounds for which retention times and transitions are
known and monitored. By changing MS conditions at 
intervals over an extended HPLC separation, several 
steroids can be determined from plasma in one run and 
there are published reviews in paediatric use (147-150). 
Several applications of LC-MS-MS profiles cover 
investigations of CAH, apparent mineralocorticoid excess,
aldosteronism, Cushing’s syndrome and adrenal insufficiency
(151-157) and disorders of sexual development (158-160).
Reference ranges for steroids in LC-MS-MS methods will
be essential, some have been produced (155,161,162).
LC-MS-MS has also improved confirmation of newborn
screening results (163-165). Steroids in urine have also 
been analysed by LC-MS-MS techniques as free steroids 
after hydrolysis (166-168) and as conjugates (169). High
throughput can be achieved in a number of ways. HPLC
with small particles (uPLC) and turbulent flow (170) has
speeded up the separation stage; on-line solid phase 
extraction  (171) and column switching (172) are in use.
Whatever system is used, the laboratory needs to look out
for signs of contamination and carry-over (173).
Bioassays
Before chemical assays for hormones, the activity could
be detected in vivo. Bioassays were insensitive and labour
intensive. These tests included for androgens the growth of
the capon comb and levator ani muscle, prostate and 
seminal vesicles of prepubertal rats injected with steroid
extracts (174). A number of novel assays look at hormone
activity (concentration) in vitro. Steroid activity using 
primary cells or cell lines that may have been modified 
genetically are in use. Three types of assay are based on 
receptor binding, cell proliferation and reporter genes.
A receptor binding assay is like a competitive steroid 
immunoassay with the antibody replaced by a receptor 
preparation. The cells may have an endogenous receptor
(Cos-7 cells, for example) or cells modified to have a 
receptor inserted that expresses the receptor protein 
(MCF-7) (175). The simplest and most sensitive oestrogen
assays look at proliferation of MCF-7 cells (E–screen)
(176,177). A-screen uses MCF-7 cells transfected with the
AR (178). Reporter assays measure the level of expression
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steroid stimulation. Cell lines and yeast cell strains are
transfected with the receptor gene and a reporter gene for
an enzyme such as luciferase, beta-galactosidase or 
chloramphenicol acetyltransferase. When the cells are 
exposed to ligand, the reporter is activated. A substrate 
is added and signal detected by luminometry, 
spectrophotometry or fluorimetry (179). Such assays have
been used for androgens in boys (180-182) and oestrogens
in girls (183-185). These assays are not yet ready for 
routine use, but have provided useful information in 
research settings and in the search for endocrine disrupting
chemicals in the environment.
Conclusions
• Immunoassay has replaced chemical tests of steroids
based on colorimetry and will remain important in the field
of steroid testing. Some investigations of paediatric 
problems can be resolved with this technology but is 
subject to interferences. 
• Chromatography can be used before immunoassays
to improve specificity, but is too labour intensive for routine use. 
• Gas-liquid chromatography with flame ionization and
electrochemical detection and high performance LC with
UV detection remains useful for measuring steroids at the
higher ranges of concentrations in biological fluids (above
100 nmol/L). GC-MS of urinary steroids is an extremely 
powerful diagnostic tool for defects in adrenal cortical 
function and will remain important in revealing the nature of
steroids in a sample without selection.
• MS is a powerful analytical tool for qualitative and 
quantitative analysis when coupled with gas and liquid 
chromatography. MS has been largely used clinically in 
specialist areas for analysis of steroids alone and in profiles.
Tandem mass spectrometry (MS-MS) is becoming more 
attractive as a routine tool and will bring benefits of new
technology to broaden applications.
• LC-MS-MS is often regarded as reference technology.
Accuracy and specificity are better than immunoassay, but
LC-MS-MS does not yet meet the higher precision 
standards achieved with GC-MS. 
• This review has considered the potential for tandem
MS in steroid analysis. Comparisons of results with other
methods and results of EQA suggest that LC-MS-MS often
shows lower results, but immense performance variation
probably through lack of skill, pressure to reduce analytical 
time, and calibration differences. Manufacturers are working
to improve that by developing “kits”-a move that will be
well received by clinical laboratories.
• Some progress has been made for peptides, but 
progress in this area is likely to be slow. Currently, proteins
have to be digested to peptide fragments.
• Bioassays are unlikely to compete routinely with 
immunoassay or MS methods.
• Clinicians should always discuss unusual results with
the laboratory, since there may be explanations and 
alternative investigations that can be analysed by a tandem
mass spectrometric approach.
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